ENTA - ENANTA PHARMACEUTICALS INC
IEX Last Trade
6.02
-0.060 -0.997%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:29:39 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$6.08
-0.06
-0.99%
Fundamental analysis
16%
Profitability
18%
Dept financing
12%
Liquidity
75%
Performance
0%
Performance
5 Days
-2.87%
1 Month
-32.30%
3 Months
-42.83%
6 Months
-50.20%
1 Year
-33.33%
2 Year
-87.04%
Key data
Stock price
$6.02
DAY RANGE
N/A - N/A
52 WEEK RANGE
$5.98 - $17.80
52 WEEK CHANGE
-$36.79
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/25/2024
Company detail
CEO: Jay R. Luly
Region: US
Website: enanta.com
Employees: 160
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: enanta.com
Employees: 160
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Enanta Pharmaceuticals, Inc. discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus.
Recent news